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Abstract: Novel 9-ethyl-9H-carbazole-3-carboxylic acid derivatives including ester, β-diketone and pyrazole were prepared and characterized 
by FT-IR, 1H NMR, 13C NMR and mass spectroscopic techniques. All synthesized compounds evaluated for their in vitro antimicrobial activities 
against four bacteria (Escherichia coli, Pseudomonas putide, Bacillus subtilis, and Streptococcus lactis) and three fungi (Aspergillus niger, 
Penicillium sp and Candida albicans). Among the compounds tested, 3a, 3b, 3c, 4a, 4b, 4c, 5a and 5b exhibited pronounced antibacterial activity 
as compared with standard drug ampicillin. Notably, carbazole based pyrazole derivatives 5a and 5b showed potent antifungal activity against 
C. albicans comparable to reference drug greseofulvin. 
 





ISTINGUISHABLE interest of synthetic organic 
chemists have attracted considerable attention to 
carbazole frame because of its derivatives that can be easily 
reformed by introducing various functional groups.[1] These 
distinct characteristics results in the broad potential 
applications of carbazole-based derivatives as industrially 
and pharmacologically important products (Figure 1).[2] 
Many recent literatures have reported that carbazole 
derivatives exhibit a variety of biological activities such as 
antimicrobial,[3–5] antiviral,[6] anticancer,[7] anti-inflamma-
tory,[8] antimala-rial,[9] antipsychotic[10] and are used in the 
treatment of obesity.[11] 
 The carbazole carboxylic acid derivatives are 
significant intermediate because the carboxylic group is 
one of the active functional group which display an 
important role in transformation of biological function, 
these compounds combining low toxicity with high 
antitumor activity.[12] Functionalized β-diketones are 
clinically important molecules showing antibacterial,[13] 
antiviral,[14] insecticidal,[15] antioxidant,[16] potential 
prophylactic antitumor[17] and pharmacophore of HIV-1 
Integrase (IN) inhibitors.[18] The synthesis of β-diketones 
containing carbazole fragment and their complexes have 
already been reported, whereas β-diketone containing 
carbazole fragments still remain unknown, though such β-
diketones should be very important and promising for use 
in optoelectronic materials.[19] β-diketones are important 
intermediates for the synthesis of medicinally important 
heterocycles such as pyrazole,[20,21] because of their 
derivatives represent one of the most active classes of 
compounds and possess a wide spectrum of biological 
activities.[22-24] Insight the literature, carbazole based 
pyrazole derivatives possesses potent antibacterial and 
antifungal activities.[25] In continuation of our studies in 
synthesizing various biologically active compounds,[26,27] in 
this study, we have synthesized and characterized the novel 
carbazole assembled esters, β-diketones and pyrazoles 
derivatives from 9-ethyl-9H-carbazole-3-carboxylic acid 
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RESULTS AND DISCUSSION 
Chemistry 
In view of the emerging biological importance of 
carbazole, it was of interest to synthesize some carbazole 
assembled esters, β-diketones and pyrazoles derivatives 
on the hope of obtaining more antimicrobial agents. Thus, 
starting compound, 9-ethyl-9H-carbazole-3-carboxylic 
acid 2 was prepared from oxidation of 9-ethyl-9H-
carbazole-3-carbaldehyde by literature method.[28] In the 
present work 2-hydroxy acetophenones 1 were treated 
with 9-ethyl-9H-carbazole-3-carboxylic acid 2 in the 
presence of phosphorous oxychloride and pyridine to 
afford the corresponding esters 3(a-e). Carbazole esters 
3(a-e) treated with strong base like potassium hydroxide 
in the presence of pyridine bring an intramolecular 
Claisen condensation as per Baker-Venkataraman (Bk-Vk) 
transformation,[29–30] resulting in 1-(9-ethyl-9H-carbazol-
3-yl)-3-(2-hydroxyphenyl) propane-1,3-dione 4(a-e). In 
the next step, cyclization of the β-diketones using 
hydrazine hydrate in ethanol at reflux temperature gave 
pyrazoles 5(a-e) as shown in Scheme 1. The Baker-
Venkataraman transformation proceeds via the formation 
of an enolate 3a followed by an intramolecular acyl 
transfer Scheme 2. 
 The structures of 3(a-e), 4(a-e) and 5(a-e) were 
confirmed by FT-IR, 1H and 13C NMR, and mass spectra. For 
example, the infrared spectra of 3(a-e) shows an intense 
absorption band at around 1735 cm−1 for –O−CO group 
occurs at higher frequencies than that of normal ketones 
because force constant of the carbonyl bond is increased 
by the electron attracting nature of adjacent oxygen atom 
and the 1HNMR spectrum of 3a contained characteristic 
singlet at δ 2.55 ppm for CO–CH3 which confirmed the 
esterification of 9-ethyl-9H-carbazole-3-carboxylic acid 2, 
aromatic protons resonated in the region δ 7.33−9.01 ppm. 
In the 13C NMR spectra of 3(a-e) showed aromatic carbon 
signals in the region of δ 108.47−145.59 ppm, whereas 
conjugated carbonyl ester appeared at δ 164.59 ppm and 
carbonyl carbon at δ 195.67 ppm. The mass spectrum of 3a 
displayed a molecular ion peaks at m/z 426 [m+1], 
427[m+2] and 429 [m+4] confirmed the compound 3a 
contained two chlorine atoms. 
 The infrared spectra of 4(a-e) shows a strong and 
characteristic band for 1,3-diketone linkage at 1677−1590 
cm−1 and 2979 cm−1 for –OH stretching. The representative 
1HNMR spectrum of 4b shows disappearance of a singlet at 
around δ 2.55 ppm (corresponding to CO–CH3) but it 
displayed two sharp singlets due to two protons at δ 16.27 
ppm and δ 12.48 ppm, which confirm the presence of enolic 
proton (since enol form in β-diketone is more stable) and 
phenolic –OH adjacent to the carbonyl group respectively. 
13C NMR spectra showed a singlet at δ 203.07 ppm due to 
ketonic carbon and at δ 168.47 ppm due to enolic carbon 
confirming the keto-enol tautomerism in β-diketone 4b. 
The negative test for ester, the presence of characteristic 
1HNMR and 13C NMR peaks are consistent with the 
structure 4b and aromatic carbon signals of compounds 
4(a-e) observed in the region of δ 109.25−142.53 ppm. The 
mass spectrum of 4b displayed a molecular ion peak at m/z 
392 [m+1]. The infrared spectrum of 5a showed the 
appearance of absorption band at 3373, 3246 and 1455cm–1 
corresponding to NH, OH and C=N functional group 
respectively. Also, its 1HNMR spectrum supported its 
structure, as it revealed the pyrazole ring protons at δ 7.26 
and two broad signals at δ 12.61 and 8.80 ppm assignable 
to OH and NH protons, respectively. The 13C NMR spectrum 
of the compounds 5(a-e) showed aromatic carbon signals 
in the region δ 109.20−140.25 ppm. 
Antibacterial and Antifungal Evaluation 
Antimicrobial activity of newly synthesized compounds 3, 4 
and 5 was evaluated against two gram negative (E. coli, P. 
putide), two gram positive (B. subtilis, S. lactis) bacterial 
strains, and three (A. niger, Penicillium sp, C. albicans) 
fungal strains using Ampicillin and Greseofulvin as a 
standard drugs respectively. The inhibition zone diameter 
(mm) and minimal inhibitory concentration (MIC) values of 
all synthesized compounds were noted in Table 1. 
Graphical representations Figure 2 and 3, inhibition zone 
diameter (mm) against a compound number (3, 4 and 5), 
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bacterial and fungal strains as compared with standard 
drugs. It was found that compounds 3(a-d), 3a, 3b and 3c 
gave stronger antibacterial efficacies and broader bioactive 
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values in the range (30−40 µg/mL) comparable to that of 
the positive control, also compounds 3d and 3e exhibit 
moderate to good inhibitory activities (75 and 90 µg/mL) 
against P. putide and B. subtilis bacterial strain respectively. 
Compounds 3a, 3b and 3c showed a broad spectrum of 
antifungal activities (45−55 µg/mL) against C. albicans and 
Penicillium sp as compared with standard drug greseo-
fulvin. Among β-diketones 4(a-e), compounds 4a, 4b and 4c 
showed good inhibition activities (35−45 µg/mL) against S. 
lactis bacterial strains, remaining members could be able to 
prevent the growth of testing bacterial strains comparable 
to the standard drug ampicillin. Compounds 4a, 4b, 4c  4d 
and 4e displayed significant inhibition activities with a MIC 
≥ 30 µg/mL against all tested fungal strains, while 
compounds 4d and 4e are passive for C. albicans fungal 
strain. Carbazole based pyrazoles 5(a-e), compounds 5a 
and 5b shows remarkable antibacterial activity against 
tested pathogens namely S. lactis, B. subtilis and P. putide 
compared to standard drug ampicillin at lowest 
concentration ranging from (35−55 µg/mL) with nearly 
equipotent of inhibition zone, compounds 5d and 5e could 
not effectively inhibit the growth of all tested bacterial 
strains. Compounds 5a and 5b showed maximum 
antifungal activities with MIC value (25 and 30 µg/mL) 
against C. albicans as compared with commercial antibiotic 
greseofulvin. While most of the compounds 3, 4 and 5 were 
not satisfactorily inhibit the growth of E. coli bacterial strain 
as compared with positive control. 
 
CONCLUSIONS 
Novel 9-ethyl-9H-carbazole-3-carboxylic acid derivatives 
including ester, β-diketone and pyrazole were prepared 
investigated for their in vitro antimicrobial activities. 
Among the synthesized compounds, compounds 3a, 3b, 3c, 
4a, 4b and 4c showed moderate to promising antimicrobial 
activities in comparison with standard drug. In addition to 
compounds 5a and 5b were identified as the most potent 
antibacterial and antifungal agents compared with 
reference compounds. As structure activity relationship  
Table 1. Antimicrobial activities(a) of the synthesized compounds 3, 4 and 5 against pathological organisms expressed as 














niger Penicillium sp 
Candida 
albicans 
3a 14 (90) 12 (80) 16(40) 20(30) 18(80) 10(80) 11(45) 
3b 18 (100) 15(90) 17(35) 20(30) 16(100) 10(100) 12(50) 
3c 11(90) 14(80) 14(40) 18(40) 19(90) 11(55) 09(80) 
3d 17(100) 18(75) 18(90) 17(80) 17(100) 12(90) 10(95) 
3e 14(100) 12(100) 15(90) 18(100) 11(90) 11(100) 08(100) 
4a 16 (100) 15(75) 14(80) 17(35) 12(90) 12(30) 09(85) 
4b 12(90) 13(65) 12(80) 17(40) 17(80) 11(30) 12(90) 
4c 11(100) 13(80) 14(90) 19(45) 13(100) 12(40) 11(80) 
4d 12(110) 17(100) 11(100) 16(90) 12(100) 12(55) NA 
4e 16 (100) 14(100) 09(110) 15(100) 15(110) 11(80) NA 
5a 16(90) 13(45) 18(35) 21(45) 17(95) 10(85) 16(25) 
5b 16(90) 16(55) 17(35) 21(50) 19(90) 10(90) 15(30) 
5c 13(100) 14(90) 16(70) 19(100) 18(85) 11(100) 09(60) 
5d 16(120) 18(100) 15(110) 15(90) 17(90) 12(90) 12(100) 
5e 14 (110) 16(95) 15(110) 16(110) 11(100) 11(100) 11(90) 
Ampicillin 24(25) 20(25) 19(25) 22(25) ----- ----- ----- 
Greseofulvin ----- ----- ----- ----- 24(25) 14(25) 14(25) 
Control 
(1%DMSO) 
NA NA NA NA NA NA NA 
(a) Inhibition zone diameters were measured for stock solutions (100μg/mL).  
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(SAR) study of all compounds were taken into account, it 
was observed that the introduction of carbazole moiety to 
β-diketone, ester and pyrazole derivatives caused enriched 
activities against most test organisms. The results also 
suggested that the antimicrobial activities of the carbazole 
derivatives were distinctly influenced by the aromatic 
substituents. Compounds 3a, 3b, 3c, 4a, 4b, 4c, 5a, 5b and 
5c with electron withdrawing substituents (Cl and Br) in the 
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phenyl ring were more potent against most of the tested 
microorganisms than compounds with electron donating 
ones. Furthermore, compounds 3e, 4e and 5e without 
substituent in the phenyl ring showed satisfactory activities 
against all tested bacterial and fungal strains. High potency 
and promising antimicrobial activity of newly synthesized 
compounds 3(a-e), 4(a-e) and 5(a-e) suggest that these 
compounds could serve as good leads for further opti-
mization and development. 
 
EXPERIMENTAL 
The recorded melting points were determined in an open 
capillary and are uncorrected. IR spectra were recorded on 
Perkin Elmer Fourier-transform infrared (FTIR) spectro-
meter from KBr pellets. The 1H NMR and 13C NMR spectra 
were recorded on Bruker Avance II (400 MHz) and Bruker 
(125 MHz) spectrometer respectively, using TMS as internal 
standard. Mass spectra were recorded on a Waters, Q-TOF 
micromass, while HRMS were scanned on Bruker impact 
HD (ESI-Q-TOF) spectrophotometer. The thin layer chroma-
tography (TLC) was carried out on precoated silica gel alu-
minum plates to check compound purity. The substituted 
2-hydroxyacetophenones are commercially available. 
In Vitro Antimicrobial Assay 
The antimicrobial activity was evaluated by the agar well 
diffusion method. The activity was determined by meas-
uring the diameter of inhibition zone (in mm). The samples 
of the tested compound concentrations (50μL, 1 mg/mL) 
were loaded into wells on the plates. All solutions were 
prepared in DMSO, and pure DMSO was loaded as a 
control. The plates were incubated at 37 ºC for 1-5 days and 
then were examined for the formation of inhibition zone. 
Each inhibition zone was measured three times to get an 
average value. The test was performed three times for each 
bacterium culture.[31] 
Minimal Inhibitory Concentration (MIC) 
Measurement 
The potato dextrose broths and microorganisms suscepti-
bility tests in nutrient media were used for the deter-
mination of MIC. The tested compounds stock 1000 µg/mL 
solutions, Ampicillin and Greseofulvin were prepared in 
DMSO followed by dilutions to 250−25 µg/mL concen-
trations. Inoculated microorganism suspensions were 
incubated at 37 °C for 1-5 days for MIC determination.[31]. 
General Procedure for Esterification of 
Compounds 3(a-e) 
A mixture of compound 1 (1.36 g, 10 mmol) and 9-ethyl-9H-
carbazole-3-carboxylic acid 2 (2.3 g, 10 mmol) was dissolv-
ed in dry pyridine (10 mL). Cooled the flask in an ice bath 
and phosphorousoxychloride (1.53g, 10 mmol) was added 
dropwise with constant stirring while maintain the 
temperature between 0−10 °C. After complete addition of 
phosphorousoxychloride, the reaction mixture was kept 
overnight at room temperature, then poured over crushed 
ice and acidified using cold dilute HCl. The off white solid 
product obtained was filtered and washed with cold dill. 
NaHCO3 solution followed by washing with cold water. 
Crude product was dried and recrystallized from ethanol to 
obtain the desired product in pure form 3(a-e), which gave 
a positive test for ester. 
2-acetyl-4, 6-dichlorophenyl 9-ethyl-9H-carbazole-3-carb-
oxylate (3a) Off white solid; Yield (73 %); Rf = 0.44 (6 % 
ethylacetate in n-hexane); m.p. 98–99 °C; IR (KBr) ṽmax/ 
cm−1: 1130 (C−Cl), 1199 (C−O), 1697 (C=O), 1731 (ester 
C=O); 1H NMR (CDCl3) δ/ppm: 1.48 (t, 3H, CH3), 2.55 (s, 3H, 
COCH3), 4.43 (q, 2H, N−CH2), 7.33 (m, 1H, ArH), 7.51 (m, 3H, 
ArH), 7.66 (d, J = 2.5 Hz,1H, ArH), 7.74 (d, J = 2.5 Hz, 1H, 
ArH), 8.18 (d, J = 7.7 Hz, 1H, ArH), 8.35 (dd, J = 1.6 & J = 7.0 
Hz, 1H, ArH), 9.01(d, J = 1.5 Hz, 1H, ArH); 13C NMR (CDCl3) 
δ/ppm: 13.84, 30.04, 37.95, 108.47, 109.10, 118.20, 
120.32, 120.93, 122.96, 123.13, 124.23, 124.37, 126.78, 
128.16, 128.39, 130.21, 131.90, 133.33, 134.67, 140.69, 
143.42, 145.18, 164.59, 195.67; MS (m/z): 426 (M+H)+. 
HRMS (ESI): calculated for C23H17Cl2NNaO3 (M+Na) 
448.047769, found 448.0480. 
2-acetyl-4-chlorophenyl 9-ethyl-9H-carbazole-3-carboxy-
late (3b) Off white solid; Yield (70 %); Rf = 0.49 (6 % 
ethylacetate in n-hexane); m.p. 112−113 °C; IR (KBr) 
ṽmax/cm−1: 1131 (C−Cl), 1200 (C−O), 1687 (C=O), 1733 (ester 
C=O); 1H NMR (CDCl3) δ/ppm: 1.49 (t, 3H, CH3), 2.56 (s, 3H, 
COCH3), 4.45 (q, 2H, N-CH2), 7.18−7.26 (m, 2H, ArH), 
7.33−7.66 (m, 4H, ArH), 7.77−8.16 (m, 2H, ArH), 8.31−8.99 
(m, 2H, ArH); 13C NMR (CDCl3) δ/ppm: 13.72, 30.28, 37.53, 
108.16, 109.05, 118.16, 119.80, 120.03, 120.90, 122.63, 
123.07, 124.49, 124.94, 126.59, 128.45, 128.90, 130.10, 
131.96, 133.82, 134.27, 140.52, 143.15, 145.23, 174.46, 
192.74; MS (m/z): 392 (M+H)+. HRMS (ESI): calculated for 
C23H18ClNNaO3 (M+Na) 414.086742, found 414.086845. 
2-acetyl-4-bromophenyl 9-ethyl-9H-carbazole-3-carboxy-
late (3c) Off white solid; Yield (67 %); Rf = 0.42 (6% 
ethylacetate in n-hexane);  m.p. 153–154 °C; IR (KBr) 
ṽmax/cm−1: 1033 (C-Br), 1239 (C−O), 1697 (C=O), 1732 (ester 
C=O); 1H NMR (CDCl3) δ/ppm: 1.47 (t, 3H, CH3), 2.62 (s, 3H, 
COCH3), 4.42 (q, 2H, N-CH2), 7.24-7.26 (m, 2H, ArH), 7.31-
7.36 (m, 2H, ArH), 7.44-7.55 (m, 3H, ArH), 8.18−8.28 (m, 2H, 
ArH). 8.93 (s, 1H, ArH); 13C NMR (CDCl3) δ/ppm: 13.97, 
33.09, 37.76, 106.98, 107.73, 108.84, 110.13, 119.35, 
119.57, 120.25, 120.45, 120.47, 122.64, 123.08, 126.37, 
127.48, 133.09, 138.90, 140.76, 143.37, 155.46, 158.07, 
172.01, 191.85; MS (m/z): 436 (M+H)+. HRMS(ESI): 
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late (3d) Off white solid; Yield (70 %); Rf = 0.52 (6% 
ethylacetate in n-hexane); m.p. 138–139 °C; IR (KBr) 
ṽmax/cm−1: 1033 (C−O), 1692 (C=O), 1731 (ester C=O); 1H 
NMR (CDCl3) δ/ppm: 1.49 (t, 3H, CH3), 2.43 (s, 3H, Ar-CH3), 
2.55 (s, 3H, COCH3), 4.44 (q, 2H, N−CH2), 7.17−7.26 (m, 2H, 
ArH), 7.32−7.40 (m, 2H, ArH), 7.49−7.67 (m, 2H, ArH), 
7.79−7.82 (m, 2H, ArH), 8.16 (m, 1H, ArH), 8.31 (m, 1H, 
ArH); 13C NMR (CDCl3) δ/ppm: 13.51, 20.98, 29.85, 37.98, 
107.94, 108.62, 119.35, 119.80, 120.48, 123.06, 123.53, 
123.97, 124.51, 126.07, 127.97, 130.31, 130.99, 133.53, 
135.39, 140.54, 143.16, 147.33, 165.97, 198.35; MS (m/z): 
372 (M+H)+. HRMS(ESI): calculated for C24H21NNaO3 
(M+Na) 394.012145, found 394.012150. 
2-acetylphenyl 9-ethyl-9H-carbazole-3-carboxylate (3e) 
Off white solid; Yield (69 %); Rf = 0.48 (6 % ethylacetate in n-
hexane); m.p. 198−199 °C; IR (KBr) ṽmax/cm−1: 1124 (C−O), 1626 
(C=O), 1706 (ester C=O); 1H NMR (CDCl3) δ/ppm: 1.44 (t, 3H, 
CH3), 2.53 (s, 3H, COCH3), 4.45 (q, 2H, N-CH2), 6.99−7.34 (m, 
3H, ArH), 7.50−7.66 (m, 4H, ArH), 7.96−8.02 (m, 1H, ArH), 
8.11−8.21 (m, 2H, ArH), 8.66-8.70 (m, 1H, Ar-H); 13C NMR 
(CDCl3) δ/ppm: 14.17, 21.64, 37.98, 109.79, 112.34, 115.63, 
116.51, 119.98, 120.02, 121.44, 121.89, 122.13, 123.30, 
125.16, 127.71, 127.93, 129.35, 134.49, 134.75, 139.84, 
142.17, 156.42, MS (m/z): 358 (M+H)+. HRMS(ESI): calculated 
for C23H19NNaO3 (M+Na) 380.175794, found 380.175801. 
General Procedure for the Synthesis of 
Compounds 4(a-e) 
Aryl ester 3 (1.0 g, 3 mmol) was dissolved in dry pyridine 
(10 mL) and to this reaction mixture powdered potassium 
hydroxide (1.65 g, 3 mmol) was added with constant 
stirring. The reaction mixture was stirred at room 
temperature for 3 h. After completion of the reaction 
(monitored by TLC), the contents were poured over 
crushed ice and acidified with conc. HCl. The pale yellow 
colored solid product obtained was filtered and 
recrystallized from ethanol to get pure compounds 4(a-e), 
which gave a negative test for ester. 
1-(3,5-dichloro-2-hydroxyphenyl)-3-hydroxy-3-(9-methyl-
9H-carbazol-3-yl)prop-2-en-1-one (4a) Pale yellow colored 
solid; Yield (73 %); Rf = 0.51 (6 % ethylacetate in n-hexane); 
m.p. 168−170 °С; IR (KBr) ṽmax/cm−1: 1155 (C−Cl), 1592 
(C=O), 2976 (enol OH), 3065 (OH); 1H NMR (DMSO-d6) 
δ/ppm: 1.36 (t, 3H, CH3), 4.50 (q, 2H, N−CH2), 7.25 (m, 1H, 
=CH enol), 7.50−7.57 (m, 2H, ArH), 7.65−7.77 (m, 2H, ArH), 
7.82-8.31 (m, 5H, ArH), 12.57 (s, 1H, OH), 16.89 (s, 1H, 
enolic H); 13C NMR (DMSO-d6) δ/ppm: 14.19, 37.71, 107.19, 
108.84, 109.06, 110.04, 110.70, 115.41, 120.25, 120.48, 
121.00, 121.65, 122.34, 122.53, 125.40, 126.36, 127.26, 
129.13, 134.05, 139.86, 142.19, 145.45, 168.06; MS (m/z): 
426 (M+H)+. HRMS (ESI): calculated for C23H17Cl2NNaO3 
(M+Na) 448.047769, found 448.047534. 
1-(5-chloro-2-hydroxyphenyl)-3-(9-ethyl-9H-carbazol-3-
yl)-3-hydroxyprop-2-en-1-one (4b) Pale yellow colored 
solid; Yield (68 %); Rf = 0.55 (6 % ethylacetate in n-hexane); 
m.p. 137−138 °С; IR (KBr) ṽmax/cm−1: 1131(C−Cl), 1591 
(C=O), 2979 (enol OH), 3065 (OH); 1H NMR (DMSO-d6) 
δ/ppm: 1.35 (t, 3H, CH3), 4.52 (q, 2H, N−CH2), 7.32 (m, 1H, 
=CH enol), 7.51−7.58 (m, 2H, ArH), 7.68−7.74 (m, 2H, ArH), 
7.80 (m, 1H, ArH), 8.0 (m, 1H, ArH), 8.28-8.36 (m, 3H, ArH), 
9.09 (m, 1H, ArH), 12.48 (s, 1H, OH), 16.27 (bs, 1H, enolic 
H); 13C NMR (DMSO-d6) δ/ppm: 14.16, 37.70, 109.26, 
110.04, 110.55, 120.15, 120.49, 121.23, 121.57, 122.38, 
122.73, 122.99, 123.34, 126.89, 127.51, 133.49, 138.59, 
140.67, 142.54, 159.75, 168.47, 203.07; MS (m/z): 392 
(M+H)+. HRMS (ESI): calculated for C23H18ClNNaO3 (M+Na) 
414.086740, found 414.086855. 
1-(5-bromo-2-hydroxyphenyl)-3-(9-ethyl-9H-carbazol-3-
yl)-3-hydroxyprop-2-en-1-one (4c) 
Pale yellow colored solid; Yield (63 %); Rf = 0.52 (6 % 
ethylacetate in n-hexane); m.p. 148−149 °С; IR (KBr) 
ṽmax/cm−1: 1023 (C-Br), 1594 (C=O), 2975 (enol OH), 3327 
(OH); 1H NMR (DMSO-d6) δ/ppm: 1.35 (t, 3H, CH3), 4.52 (q, 
2H, N-CH2), 6.98 (m, 1H, =CH enol), 7.26-7.54 (m, 3H, ArH), 
7.69-8.05 (m, 4H, ArH), 8.23-8.32 (m, 2H, ArH), 9.06 (m, 1H, 
ArH), 11.73 (s, 1H, OH), 12.61 (s, 1H, enolic H); 13C NMR 
(DMSO-d6) δ/ppm: 14.18, 37.76, 106.30, 109.05, 109.79, 
110.92, 111.90, 119.36, 119.80, 120.99, 121.88, 123.08, 
124.20, 124.95, 129.57, 133.30, 138.22, 140.53, 141.96, 
147.77, 154.78, 164.32, 177.15; MS (m/z): 436 (M+H)+. 
HRMS(ESI): calculated for C23H18BrNNaO3 (M+Na) 
458.046015, found 458.047019. 
3-(9-ethyl-9H-carbazol-3-yl)-3-hydroxy-1-(2-hydroxy-5-
methylphenyl)prop-2-en-1-one (4d) 
Pale yellow colored solid; Yield (65 %); Rf = 0.49 (6 % 
ethylacetate in n-hexane); m.p. 116−117 °С; IR (KBr) 
ṽmax/cm−1: 1594 (C=O), 3056 (enol OH), 3325 (OH); 1H NMR 
(DMSO-d6) δ/ppm: 1.35 (t, 3H, CH3), 2.64 (s, 3H, Ar−CH3), 
4.50 (q, 2H, N−CH2), 6.96 (m, 1H, =CH enol), 7.26−7.29 (m, 
1H, ArH), 7.50−7.55 (m, 2H, ArH), 7.63−7.70 (m, 3H, ArH), 
7.96−8.29 (m, 3H, ArH), 8.80 (m, 1H, ArH), 11.73 (s, 1H, OH), 
12.61 (s, 1H, enolic H); 13C NMR (DMSO-d6) δ/ppm: 14.19, 
28.66, 37.54, 108.39, 109.07, 109.59, 110.47, 110.70, 
119.80, 120.76, 121.00, 122.86, 126.37, 127.48, 133.08, 
137.77, 138.22, 139.64, 142.18, 147.10, 150.61, 159.40, 
168.06, 203.08; MS (m/z): 372 (M+H)+. HRMS(ESI): 




Pale yellow colored solid; Yield (69 %); Rf = 0.56 (6 % 
ethylacetate in n-hexane); m.p. 134−135 °С; IR (KBr) 
ṽmax/cm−1: 1677 (C=O), 3059 (enol OH), 3327 (OH); 1H NMR 
(DMSO-d6) δ/ppm: 1.35 (t, 3H, CH3), 4.50 (q, 2H, N-CH2), 
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(m, 2H, ArH), 7.80−7.89 (m, 2H, ArH), 8.06−8.32 (m, 2H, 
ArH), 8.77−8.85 (m, 2H, ArH), 8.97 (m, 1H, ArH), 11.26 (s, 
1H, OH), 12.50 (s, 1H, enolic H); 13C NMR (DMSO-d6) δ/ppm: 
14.19, 37.75, 109.28, 109.58, 110.47, 111.44, 120.47, 
120.99, 121.66, 121.88, 122.11, 122.84, 123.30, 123.98, 
124.95, 125.83, 126.59, 127.26, 127.71, 128.89, 131.96, 
160.36, 168.95; MS (m/z): 358 (M+H)+. HRMS(ESI): 
calculated for C23H19NNaO3 (M+Na) 380.175694, found 
380.175701. 
General Procedure for the Synthesis of 
Compounds 5(a-e) 
β-diketones 4 (0.35g, 1 mmol) was taken in ethanol (10 mL) 
and to this reaction mixture hydrazine hydrate (1.5g, 3 
mmol) was added. The reaction mixture was heated under 
reflux for 3 h. After completion of the reaction (monitored 
by TLC) the contents were allowed to attain room 
temperature, then poured into crushed ice and acidified 
with glacial acetic acid. The brown colored solid product 
obtained was filtered and recrystallized from ethanol to get 
pure products 5(a-e). 
2,4-dichloro-6-(5-(9-ethyl-9H-carbazol-3-yl)-1H-pyrazol-3-
yl)phenol (5a) 
Brown solid; Yield (72 %); Rf = 0.50 (7 % ethylacetate in n-
hexane); m.p. 132−133 °С; IR (KBr) ṽmax/cm−1: 1189 (C−Cl), 
1455 (C=N), 3246 (NH), 3373 (OH); 1H NMR (DMSO-d6) 
δ/ppm: 1.35 (t, 3H, CH3), 4.49 (q, 2H, N-CH2), 7.26 (m, 1H, 
CH pyrazole), 7.50−7.54 (m, 3H, ArH), 7.66−7.70 (m, 3H, 
ArH), 7.94−8.29 (m, 3H, ArH), 8.80 (s, 1H, NH), 12.61 (s, 1H, 
OH); 13C NMR (DMSO-d6) δ/ppm: 13.86, 37.79, 98.96, 
108.92, 109.20, 111.12, 117.86, 118.65, 118.94, 119.20, 
119.55, 120.60, 122.58, 123.48, 126.03, 126.32, 126.52, 
129.01, 131.82, 140.28, 140.50, 155.24; MS (m/z): 422 
(M+H)+. HRMS (ESI): calculated for C23H18Cl2N3O (M+H)+ 
422.082144, found 422.082963. 
4-chloro-2-(5-(9-ethyl-9H-carbazol-3-yl)-1H-pyrazol-3-yl) 
phenol (5b) 
Brown solid; Yield (70 %); Rf = 0.52 (7 % ethylacetate in n-
hexane); m.p. 178−179 °С; IR (KBr) ṽmax/cm−1: 1026 (C−Cl), 
1438 (C=N), 3050 (NH), 3385 (OH); 1H NMR (DMSO-d6) 
δ/ppm: 1.36 (t, 3H, CH3), 4.54 (q, 2H, N−CH2), 7.23−7.28 (m, 
1H, CH pyrazole), 7.30−7.35 (m, 1H, ArH), 7.50−7.58 (m, 2H, 
ArH), 7.62−7.70 (m, 1H, ArH), 7.73−7.82 (m, 2H, ArH), 
7.88−8.37 (m, 4H, ArH), 9.08 (s, 1H, NH), 12.46 (s, 1H, OH); 
13C NMR (DMSO-d6) δ/ppm: 13.85, 37.92, 108.08, 108.97, 
109.21, 113.63, 114.32, 119.93, 120.29, 120.67, 120.80, 
120.92, 121.48, 122.64, 123.34, 124.70, 125.77, 126.18, 
126.43, 127.00, 128.50, 140.64, 142.17, 181.64; MS (m/z): 
388 (M+H)+. HRMS (ESI): calculated for C23H19ClN3O (M+H)+ 
388.121116, found 388.121056. 
4-bromo-2-(5-(9-ethyl-9H-carbazol-3-yl)-1H-pyrazol-3-yl) 
phenol (5c) 
Brown solid; Yield (68 %); Rf = 0.48 (7 % ethylacetate in  
n-hexane); m.p. 143−144 °С; IR (KBr) ṽmax/cm−1: 1055 
(C−Br), 1451(C=N), 3052 (NH), 3327 (OH); 1H NMR (DMSO-
d6) δ/ppm: 1.36 (t, 3H, CH3), 4.51 (q, 2H, N−CH2), 7.22 (m, 
1H, CH pyrazole), 7.28−7.51 (m, 3H, ArH), 7.53−7.68 (m, 3H, 
ArH), 7.75−8.34 (m, 4H, ArH), 9.08 (s, 1H, NH), 12.34 (s, 1H, 
OH); 13C NMR (DMSO-d6) δ/ppm: 13.74, 37.53, 98.84, 
108.83, 109.79, 111.90, 117.93, 118.15, 118.61, 119.10, 
119.79, 120.25, 122.12, 123.31,123.77, 124.93, 125.83, 
129.79, 131.42, 139.85, 140.19, 152.08; MS (m/z): 432 
(M+H)+. HRMS (ESI): calculated for C23H19 BrN3O (M+H)+ 
432.141115, found 432.141156. 
2-(5-(9-ethyl-9H-carbazol-3-yl)-1H-pyrazol-3-yl)-4-
methylphenol (5d) 
Brown solid; Yield (71 %); Rf = 0.56 (7 % ethylacetate in n-
hexane); m.p. 123−124 °С; IR (KBr) ṽmax/cm−1: 1439(C=N), 
3054(NH), 3385 (OH); 1H NMR (DMSO-d6) δ/ppm: 1.49 (t, 
3H, CH3), 2.55 (s, 3H, Ar-CH3), 4.44 (q, 2H, N−CH2), 6.99 (m, 
1H, CH pyrazole), 7.29−7.45 (m, 3H, ArH), 7.46−7.51 (m, 2H, 
ArH), 7.53−8.16 (m, 5H, ArH), 10.20 (s, 1H, NH), 10.91 (s, 
1H, OH); 13C NMR (DMSO-d6) δ/ppm: 13.96, 28.84, 37.98, 
83.18, 108.83, 109.28, 112.54, 117.04, 118.15, 118.60, 
119.79, 121.21, 122.66, 123.30,125.16, 127.93, 128.45, 
129.57, 134.75, 139.84, 142.85, 156.64, 168.06, 170.81; MS 
(m/z): 368 (M+H)+. HRMS (ESI): calculated for C24H22N3O 
(M+H)+ 368.101135, found 368.101179. 
2-(5-(9-ethyl-9H-carbazol-3-yl)-1H-pyrazol-3-yl) phenol (5e) 
Brown solid; Yield (69 %); Rf = 0.49 (7 % ethylacetate in n-
hexane); m.p. 151−152 °С; IR (KBr) ṽmax/cm−1: 1560 (C=N), 
3363 (NH), 3676 (OH); 1H NMR (DMSO-d6) δ/ppm: 1.42 (t, 
3H, CH3), 4.48 (q, 2H, N−CH2), 6.93 (m, 1H, CH pyrazole), 
7.05 (m, 1H, ArH), 7.25−7.33 (m, 2H, ArH), 7.48−7.65 (m, 
4H, ArH), 7.94-8.17 (m, 4H, Ar-H), 9.11(s, 1H, NH), 12.31 (s, 
1H, OH); 13C NMR (DMSO-d6) δ/ppm: 13.96, 37.76, 98.62, 
108.61, 109.80, 117.26, 118.60, 119.80, 120.99, 122.10, 
123.08, 123.98, 125.61, 126.81, 127.92, 128.22, 129.10, 
134.26, 139.41, 142.40, 151.50, 157.31; MS (m/z): 354 
(M+H)+. HRMS (ESI): calculated for C23H20N3O (M+H)+ 
354.112130, found 354.112190. 
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